Back
Compare AU
Compare L1IF vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the L1 Capital International (Unhedged) Active ETF (L1IF) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
L1IF | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 2 | 67 |
Median incremental investment | $10,065.14 | $738.73 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $17,760.73 | $1,894.68 |
Average age group | 26 - 35 | > 35 |
Key Summary
L1IF | DRUG | |
|---|---|---|
Strategy | L1IF.AX was created on 2023-11-22 by L1 Capital. The fund's investment portfolio concentrates primarily on total market equity. The objective of the Fund is to outperform the Benchmark net of fees and expenses over rolling 5 year periods. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | HCA Healthcare Inc (8.48 %) AerCap Holdings NV (8.30 %) Microsoft Corp (7.47 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Financials (33.97 %) Consumer Discretionary (19.83 %) Health Care (13.03 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 1.2 % | 0.57 % |
Key Summary
L1IF | DRUG | |
|---|---|---|
Issuer | L1 Capital | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 1.2 % | 0.57 % |
Price | $6.94 | $8.51 |
Size | N/A | $162.790 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 2.46 % | 1.97 % |
Market | ASX | ASX |
First listed date | 21/11/2023 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
L1IF | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 2 | 67 |
Median incremental investment | $10,065.14 | $738.73 |
Median investment frequency | Fortnightly | Monthly |
Median total investment | $17,760.73 | $1,894.68 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
L1IF | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
L1IF | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Higher management fee | Lower management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |